MindMaze Therapeutics Holding SA
relieftherapeutics.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2023 20-F, filed Apr 30, 2024. Its latest SEC filing is a 424B3 from Apr 16, 2026.
20-F for FY2023, filed Apr 30, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops and licenses treatments and medical foods for rare skin, metabolic and respiratory conditions to pharmaceutical partners.
20-F for FY2023, filed Apr 30, 2024We are a Swiss, commercial-stage biopharmaceutical company committed to delivering innovative treatment options with the potential for…View ↗
In accordance with this strategy, on March 21, 2024 we entered into an exclusive license and supply agreement with Eton Pharmaceuticals…View ↗
PKU GOLIKE® in phenylketonuria (PKU). We recently announced a license and supply relationship with Eton Pharmaceuticals, Inc. to ensure the…View ↗
Relief Therapeutics’ portfolio consists of a balanced mix of marketed, revenue-generating products and globally patented drug delivery…View ↗
Who Were Their Customers?
The company works with license and collaboration partners that receive rights to research, develop, manufacture and commercialize products, and also sells products to customers.
20-F for FY2023, filed Apr 30, 2024
20-F for FY2023, filed Apr 30, 2024
transactions. In 2023, the three largest customers of the Group represented 12.5%, 6.4% and 6.1%, respectively, of the total revenue (2022…View ↗
Loading...
